- |||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Characteristics of responders and non-responders to Tezepelumab in a complex, real-world severe asthma population (PS-11; Poster board no. 17) - May 31, 2024 - Abstract #ERS2024ERS_1317;
The detection of oxidative stress by electrochemical sensors can open new avenues for evaluating epithelial damage and to identify patients eligible to alarmin targeted biologics. Whilst there was a statistically significant response to Tezepelumab in this real-world setting, there were no clear demographic or clinical characteristics that were predictive of a more favourable response to it, which clearly identifies an area for further study.
- |||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Relationship between FeNO suppression and Clinical Remission with Tezepelumab in Severe Asthma (PS-11; Poster board no. 11) - May 31, 2024 - Abstract #ERS2024ERS_1311;
Whilst there was a statistically significant response to Tezepelumab in this real-world setting, there were no clear demographic or clinical characteristics that were predictive of a more favourable response to it, which clearly identifies an area for further study. In a real-world cohort of SA patients, tezepelumab led to marked clinical responses in both biologic na
- |||||||||| Review, Journal: Navigating Biologic Therapies in Elderly Asthma. (Pubmed Central) - May 22, 2024
In summary, this review navigates the current landscape of biologic therapies for elderly asthmatics, offering valuable insights for various stakeholders, including researchers, healthcare providers, and policymakers, to advance asthma care in this vulnerable population. We propose that future research should concentrate on tailored, evidence-based approaches to address the undertreatment of elderly asthma patients.
- |||||||||| Review, Journal: Advancements in biologic therapy in eosinophilic asthma. (Pubmed Central) - Apr 29, 2024
Biological therapy for asthma targeting the IgE, IL-4, IL-5, IL-13, and TSLP pathways are shown to have benefit for the treatment of eosinophilic asthma, as exemplified in real world studies. When choosing the right biological agent factors such as phenotype, comorbidities, and cost-effectiveness of the biologic agent must be taken into consideration.
- |||||||||| Journal: Biological treatments in childhood asthma. (Pubmed Central) - Apr 24, 2024
However, the choice of the most appropriate biologics remains a pending issue. On the other hand, to the extent that several of the biologics have been available for a relatively short time, the most robust evidence in terms of efficacy and safety in children is that of omalizumab.
- |||||||||| Journal: New biologics for food allergy. (Pubmed Central) - Apr 24, 2024
Dupilumab, despite limited success as monotherapy, shows promise as an adjunct for OIT. Careful consideration of treatment goals, patient preferences, and the evolving landscape of biologics will shape future clinical practice, offering allergists an expanded toolbox for personalized food allergy management.
- |||||||||| Journal: Role of biologics in severe food allergy. (Pubmed Central) - Apr 24, 2024
Despite the persisting challenges of economic constraints and the need for further safety studies, biologics offer a promising avenue for improving the quality of life for individuals with food allergies. Ongoing research and collaborative efforts are imperative to fully realize the transformative potential inherent in these emerging therapeutic frontiers.
- |||||||||| Journal: Precision care in the treatment of pediatric asthma. (Pubmed Central) - Apr 24, 2024
Ongoing research and collaborative efforts are imperative to fully realize the transformative potential inherent in these emerging therapeutic frontiers. An understanding of underlying immunologic and genetic mechanisms affecting the development of asthma in pediatric patients has resulted in the production of numerous targeted therapies that have led to improvement in lung function and reduced exacerbation burden.
- |||||||||| Review, Journal: Interplay of cytokines in the pathophysiology of atopic dermatitis: insights from Murin models and human. (Pubmed Central) - Apr 9, 2024
In addition, clinical trials with fezakinumab, targeting IL-22, have demonstrated promising results, particularly in severe AD cases...Similarly, thymic stromal lymphopoietin (TSLP), integral to type 2 immune responses, induces dermatitis in animal models and is elevated in human AD, yet clinical treatments like tezepelumab exhibit limited efficacy...Consequently, this review delineates the distinct roles of cytokines in the pathogenesis of AD, juxtaposing their significance in human AD from clinical trials against insights gleaned from AD mouse models. This approach will improve our understanding of interspecies variation and facilitate a deeper insight into the pathogenesis of AD in humans.
- |||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Journal: Development of a novel humanized anti-TSLP monoclonal antibody HZ-1127 with anti-allergic diseases and cancer potential. (Pubmed Central) - Apr 3, 2024
Furthermore, HZ-1127 dramatically inhibits TSLP-dependent STAT5 activation and is more potent than Tezepelumab, which is an FDA-approved humanized mAb against TSLP for severe asthma treatment in inhibiting TSLP-induced CCL17 and CCL22 chemokines secretion in human peripheral blood mononuclear cells. Our pre-clinical study demonstrates that HZ-1127 may serve as a potential therapeutic agent for allergic diseases and cancer.
- |||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Journal: A dual computational and experimental strategy to enhance TSLP antibody affinity for improved asthma treatment. (Pubmed Central) - Mar 31, 2024
The initial affinity of the T6 antibody for TSLP was lower than the benchmark antibody AMG157...Our findings demonstrate the potential of computer-assisted techniques in expediting antibody affinity maturation, thereby reducing both the time and cost of experiments. The integration of computational methods with experimental approaches holds great promise for the development of targeted therapeutic antibodies for TSLP-related diseases.
- |||||||||| INFLAMMATORY RHEUMATISMS UPON TARGETED THERAPIES FOR ASTHMA, THE RITA STUDY (Poster View) - Mar 29, 2024 - Abstract #EULAR2024EULAR_1737;
This series found that discontinuing targeted therapy for asthma resulted in asthma relapse in 50% of cases, while the rheumatism resolved in 50% of cases. In this series, the use of targeted therapy for asthma maintenance, in combination with methotrexate, and targeted therapy for inflammatory rheumatism (when methotrexate was ineffective), proved to be both effective and safe.
- |||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Review, Journal: Tezepelumab for Severe Asthma: One Drug Targeting Multiple Disease Pathways and Patient Types. (Pubmed Central) - Mar 25, 2024
Furthermore, in all these asthma phenotypes, tezepelumab demonstrated higher efficacy in reducing exacerbations requiring hospitalizations or emergency department visits versus placebo. In patients with severe uncontrolled asthma, who commonly have multiple drivers of inflammation and disease, tezepelumab may modulate airway inflammation more extensively, as other available biologics block only specific downstream components of the inflammatory cascade.
- |||||||||| Evaluation of Clinical Remission Indicators in Asthma Patients Treated With Biologics in a Real-world Setting (San Diego Convention Center, Area D (Hall A-B2, Ground Level)) - Mar 17, 2024 - Abstract #ATS2024ATS_8858;
The findings of this study reveal the infrequent capture of the different components of CR endpoint in routine practice, thereby limiting the comprehensive evaluation of CR. This low coverage suggests the need for standardized assessment protocols that encompass all domains to enable accurate assessment of asthma remission.
- |||||||||| prednisone / Generic mfg., Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Journal: Real-life experience after 3 months with tezepelumab before marketing approval. (Pubmed Central) - Mar 13, 2024
NCT05324137. In this preliminary real-world experience prior to the official approval of tezepelumab in Spain, this monoclonal antibody showed promising results and suggests its potential as a valuable alternative for the treatment of severe asthma.
- |||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Journal: The last step to achieve barrier damage control. (Pubmed Central) - Mar 3, 2024
Treatment with anti-TSLP monoclonal antibodies showed efficacy in severe asthma and clinical trials for other eosinophilic diseases are ongoing. The aim of this perspective review is to analyse current advances and future applications of TSLP inhibition to control barrier damage.
- |||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Trial completion date, Trial primary completion date: REVERT: REVErsing Airway Remodelling With Tezepelumab (clinicaltrials.gov) - Mar 2, 2024
P3, N=90, Recruiting,
The aim of this perspective review is to analyse current advances and future applications of TSLP inhibition to control barrier damage. Trial completion date: Mar 2025 --> Jun 2026 | Trial primary completion date: Mar 2025 --> Dec 2025
- |||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Enrollment change, Trial completion date, Trial primary completion date, HEOR, Real-world evidence, Real-world: ASCENT: A Study for Observing Severe Asthma in Patients Treated With Tezepelumab (clinicaltrials.gov) - Feb 28, 2024
P=N/A, N=550, Recruiting,
Trial completion date: Mar 2025 --> Jun 2026 | Trial primary completion date: Mar 2025 --> Dec 2025 N=200 --> 550 | Trial completion date: Dec 2024 --> Nov 2025 | Trial primary completion date: Dec 2024 --> Nov 2025
- |||||||||| Review, Journal: Role of IL-4 and IL-13 in Cutaneous T Cell Lymphoma. (Pubmed Central) - Feb 24, 2024
This review analyzes current knowledge on the IL-4/IL-13 axis in mycosis fungoides and Sezary syndrome, the most common types of CTCL, examining existing literature on the pathogenetic implications with a focus on investigational treatments. Clinical trials and case reports are required to shed light on novel uses of medications in various diseases, and ongoing research into the role of IL-4/IL-13 axis blockers in CTCL therapy might not only improve the management of disease-related pruritus but also provide in-depth insights on the pathophysiologic mechanisms of CTCL.
- |||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Trial completion, Phase classification: COURSE: Tezepelumab COPD Exacerbation Study (clinicaltrials.gov) - Feb 22, 2024
P2, N=337, Completed,
Clinical trials and case reports are required to shed light on novel uses of medications in various diseases, and ongoing research into the role of IL-4/IL-13 axis blockers in CTCL therapy might not only improve the management of disease-related pruritus but also provide in-depth insights on the pathophysiologic mechanisms of CTCL. Active, not recruiting --> Completed | Phase classification: P2a --> P2
- |||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
A Real-world Experience on New Starts Versus Biological Switchers for Tezepelumab in Severe Asthma (San Diego Convention Center, Area F (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_5731;
Our cohort suggests that new tezepelumab starts tended to have more non-T2 inflammation characteristics (comorbidities, OCS dependence and biomarkers) than those switched from another biologic agent. These study findings highlight current practice patterns, however given the broad mechanism of action (such as application in T2 high asthma) of tezepelumab can be considered even when selecting biologics for patients with SA as the first line agent.
- |||||||||| Effect of Biologics on Biomarkers of Type 2 Inflammation in Asthma: A Review of the Literature (San Diego Convention Center, Area F (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_5728;
Tezepelumab impacted nearly all biomarkers, and dupilumab impacted many biomarkers but had no effect on blood or tissue eosinophils, with no reported outcomes for IL-5. Benralizumab and mepolizumab showed the greatest reductions in BEC and reduced tissue and sputum eosinophils, while omalizumab substantially reduced IgE and modestly reduced many other biomarkers.
- |||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Real-world Experience With Tezepelumab for Severe Asthma in an Academic Medical Center (San Diego Convention Center, Area F (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_5722;
05). ConclusionsIn our real-world analysis, tezepelumab was effective for patients with severe asthma and resulted in fewer clinically significant exacerbations in the year after treatment initiation compared to the 12 months prior to treatment.
- |||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Effect of Tezepelumab on Exercise Tolerance in Patients With Severe, Uncontrolled Asthma From the NAVIGATOR Study (San Diego Convention Center, Area F (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_5715;
P3
A greater proportion of tezepelumab recipients than placebo recipients reported improvements in SGRQ exercise tolerance items at week 24 (the first time point assessed) and week 52; this was observed across all items assessed. These data further support the efficacy of tezepelumab in improving asthma symptoms and health-related quality of life in a broad population of patients with severe, uncontrolled asthma.
- |||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Efficacy of Tezepelumab in Black or African American Patients: A Pooled Analysis of The PATHWAY and NAVIGATOR Studies (San Diego Convention Center, Area F (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_5711;
P2, P3, P4
The small sample size of BAA patients limited the precision in estimating the treatment effect of tezepelumab, particularly with ACQ-6 score changes. Further studies, such as the ongoing phase 4 PASSAGE study (NCT05329194) that will enroll larger numbers of BAA patients, would be valuable to describe the clinical outcomes of tezepelumab treatment in this patient population.
- |||||||||| Use of Biologics and Asthma Remission in Underrepresented Patient Populations (San Diego Convention Center, Area F (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_5710;
By identifying individuals benefiting from specific biologic therapy, more patients with severe asthma may attain disease control and be started on the biologic most likely to benefit them. This is particularly critical for the vulnerable asthma patients from underrepresented populations.
- |||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen, Xolair (omalizumab) / Roche, Novartis
A Combination of Tezepelumab and Omalizumab for Severe Persistent Asthma (San Diego Convention Center, Area H (Hall H, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_5640;
A while Later she was started on Azathioprine and Theophylline which showed a good effect with decreased exacerbations...Subsequently, she was desensitized to IV hydrocortisone which helped in managing her acute exacerbations, and then desensitized to oral prednisolone and kept on it chronically which helped in preventing her exacerbations...DiscussionSince Tezepelumab was added to the regimen along with Omalizumab, the patient had fewer exacerbations to 2 times/year compared to the previous year with 6 exacerbations. Theophylline was stopped completely, and prednisolone was tapered to 5 mg daily, hoping that it could be stopped completely in the near future.
- |||||||||| ketamine / Generic mfg.
Ketamine Chronicles: A Breath of Fresh Air in Status Asthmaticus (San Diego Convention Center, Area H (Hall H, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_5639;
This patient's subsequent improvement in respiratory symptoms and vital sign stabilization is evidence of ketamine's therapeutic potential in managing refractory status asthmaticus. While this case lends support to the growing interest in ketamine as a treatment option, further studies, and clinical trials are essential to fully assess its efficacy and safety and to identify potential target populations.
- |||||||||| Dupixent (dupilumab) / Sanofi, Regeneron
Psoriasiform Dermatitis During Dupilumab Treatment in Asthma and Allergic Bronchopulmonary Aspergillosis (ABPA) (San Diego Convention Center, Area H (Hall H, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_5633;
She was switched to voriconazole and omalizumab was eventually added...The ABPA again flared and mepolizumab was begun without success...The plaque psoriasis has since required Apremilast for control...An already upregulated IL-17/IL-23 cytokine milieu in the setting of active chronic co-infections in both cases may have further predisposed this shift during time of dupilumab therapy. Future considerations for therapy may involve targeting upstream to inhibit both Th2 and Th17 pathways, such as Tezepelumab.
- |||||||||| Dupixent (dupilumab) / Sanofi, Regeneron, Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen, Xolair (omalizumab) / Roche, Novartis
Hyperimmunoglobulin E Syndrome: A Rare Autoimmune Masquerade of Th2 Asthma (San Diego Convention Center, Area H (Hall H, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_5629;
Dupilumab, an anti-IL4 and IL3 monoclonal antibody, was then used and the patient had control of asthma symptoms, and a decline in serum IgE levels. This case demonstrates a rare autoimmune masquerade of Th2 asthma while also demonstrating novel treatments with biologics.
- |||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
An Example of Tezepelumab Used to Treat Occupational Asthma (San Diego Convention Center, Area H (Hall H, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_5626;
This case shows that tezepelumab may be a viable treatment option in patients with OA. Further study of biologics in OA is warranted.
|
